MSLN and malignant mesothelioma: Additionally, EGCG was confirmed to enhance antigen-specific immunotherapy efficacy of mesothelin-specific chimeric DNA vaccine by boosting the maturation of DCs, which is promising to offer an effective approach for immunotherapy in malignant mesothelioma, ovarian cancer, and pancreatic cancer (55).